United BioSource Corporation, Barcelona, Spain.
J Med Econ. 2013;16(5):648-56. doi: 10.3111/13696998.2013.775133. Epub 2013 Mar 15.
This time-and-motion study aimed to quantify healthcare personnel time associated with routine anemia-management tasks for maintenance therapy with C.E.R.A. (continuous erythropoietin receptor activator) that treats anemia with once-monthly injections versus other erythropoiesis-stimulating agents ('Other ESAs'), including shorter-acting ESAs (epoetin alfa, epeotin beta) and darbepoetin alfa.
This was a non-interventional, observational study where patients were treated for anemia according to individual center practices. Time taken to complete frequent anemia-management tasks for both groups (C.E.R.A. vs. 'Other ESAs') was recorded and potential annual time savings per patient and per center following assumed 100% uptake of C.E.R.A. once monthly were estimated.
For 'Other ESAs', the average total time spent per patient per year on frequent anemia management-related tasks ranged from 48 minutes in Spain to 265 minutes in Poland. For C.E.R.A. once monthly, the average total time spent per patient per year ranged from 12 minutes in Spain to 39 minutes in Poland, a reduction in actual time spent of 76-89% versus 'Other ESAs'. 100% adoption of C.E.R.A. once monthly may result in average annual time savings of 26-553 hours, a reduction of 67-95% depending on center size and frequency distribution of 'Other ESAs'.
Due to variability in treatment practices between centers (differences in task, description and frequency distribution of 'Other ESAs') and the small numbers of centers participating in each country, it is difficult to generalize annual per patient time results to reflect each country. Per center results should be interpreted with caution as they were derived based on specific center sizes that may not reflect typical center sizes in the country.
Adoption of C.E.R.A. once monthly could offer substantial time savings on frequent anemia management-related tasks versus 'Other ESAs'; allowing re-allocation of scarce resources to other aspects of patient care.
本时间与动作研究旨在量化与 C.E.R.A.(持续红细胞生成素受体激活剂)维持治疗相关的医疗保健人员时间,该药物用于治疗贫血,每月注射一次,与其他促红细胞生成素刺激剂(“其他 ESA”)相比,包括作用时间更短的 ESA(epoetin alfa、epeotin beta)和达贝泊汀 alfa。
这是一项非干预性、观察性研究,根据各个中心的实践对患者进行贫血治疗。记录两组(C.E.R.A.与“其他 ESA”)完成常见贫血管理任务所花费的时间,并假设每月 100%接受 C.E.R.A.治疗后,每位患者和每个中心的潜在年度节省时间进行了估计。
对于“其他 ESA”,每位患者每年用于频繁贫血管理相关任务的平均总时间范围从西班牙的 48 分钟到波兰的 265 分钟。对于每月一次的 C.E.R.A.,每位患者每年的平均总时间范围从西班牙的 12 分钟到波兰的 39 分钟,与“其他 ESA”相比,实际花费的时间减少了 76-89%。每月 100%使用 C.E.R.A.治疗可能会导致平均每年节省 26-553 小时,具体节省比例取决于中心规模和“其他 ESA”的频率分布,在 67-95%之间。
由于各个中心之间的治疗实践存在差异(任务、“其他 ESA”的描述和频率分布存在差异),并且每个国家参与的中心数量较少,因此难以将每位患者的年度时间结果推广到反映每个国家的情况。每个中心的结果都应谨慎解释,因为它们是基于特定中心规模得出的,而这些中心规模可能无法反映该国的典型中心规模。
与“其他 ESA”相比,每月使用一次 C.E.R.A.治疗可在频繁的贫血管理相关任务上节省大量时间;允许将稀缺资源重新分配到患者护理的其他方面。